CTI Clinical Trial and Consulting Services and ASKA Research announce global collaboration in drug and medical device development, education services, and clinical trial management.
Cincinnati, OH, and Vancouver, Canada-May 5, 2008-CTI Clinical Trial and Consulting Services (CTI) and ASKA Research are proud to announce that they have partnered to expand both companies’ global reach and to better serve their clients in all aspects of drug and medical device development, education services, and clinical trial management.
Through this relationship, ASKA will be able to offer full service clinical trial service offerings to their existing sponsors and have the ability to engage sponsors in trials to be conducted in Canada and the United States. In addition, ASKA will now have access to CTI’s expertise in health care communications and continuing medical education. These developments will enable ASKA to offer a comprehensive set of resources to their clients.
The relationship with ASKA provides CTI access to a vast pool of experienced and qualified monitoring staff located throughout Canada. This will provide sponsors the opportunity to expand trials into Canada and have these trials managed by local professional staff possessing strong relationships with Canadian sites and investigators leading to better management of trials, enhanced enrollment, and cost savings through the engagement of local monitoring staff.
CTI is a fully integrated drug and market development company with headquarters based in Cincinnati, OH. CTI offers a full range of services in the therapeutic areas of transplantation (solid organ, bone marrow, and stem cells), infectious disease, hepatitis, end-stage organ disease (heart, liver, lung, and kidney), hematology, and immunology.
CTI has successfully worked with U.S. and global pharmaceutical and biotechnology companies specializing in managing trials and programs tailored toward the critically and chronically ill patient populations. Along with their full range of CRO services, CTI also provides drug development consulting services, professional education and healthcare communication services.
“Over the past year we have worked with CTI on a number of projects. We are impressed with the deep therapeutic expertise they possess as well as the full scope of services they provide to sponsors,” noted Valerie Willetts, founder, president, and chief executive officer of ASKA Research. “Partnering with CTI allows ASKA to offer a sponsor a full range of services-from protocol development and regulatory consulting to data management, statistical analysis and clinical trial report writing.”
ASKA Research, headquartered in Vancouver, Canada, provides quality assurance, education/training, and outsourced clinical trial management staffing services. Through a network of 250 professionals, ASKA can meet the staffing needs of sponsors for their trials in North America.
“ASKA Research has developed an outstanding network of qualified and experienced monitoring staff throughout Canada. They complement our reach by allowing CTI to extend our services throughout Canada in a very cost effective manner,” said Timothy J. Schroeder, president and chief executive officer of CTI Clinical Trial and Consulting Services. “Moreover, this represents another step forward in CTI’s global expansion to better serve our clients.”
In addition to providing clinical trial services to sponsors, CTI and ASKA will be exhibiting together at the 2008 DIA conference in Boston, Massachusetts from June 22–25, 2008. By exhibiting together-along with partners from Europe and Japan-CTI and ASKA will be able to present to sponsors a well developed global network of providers to meet their clinical trial management needs.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.